Addex Therapeutics Reports Q3 2025 Financial Results

Addex Therapeutics Ltd (ADR) ( (ADXN) ) has released its Q3 earnings. Here is a breakdown of the information Addex Therapeutics Ltd (ADR) presented to its investors.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing allosteric modulators for neurological disorders, operating primarily in the pharmaceutical industry. The company is listed on the SIX Swiss Exchange and the Nasdaq Stock Market under the ticker symbol ADXN.

In its Q3 2025 earnings report, Addex Therapeutics reported a net loss of CHF 4.89 million for the nine-month period ending September 30, 2025, compared to a net profit of CHF 8.26 million in the same period in 2024. The company’s revenue from contracts with customers was CHF 29,724, significantly lower than the CHF 402,594 reported in the previous year.

Key financial metrics indicate a challenging period for Addex Therapeutics, with total assets decreasing from CHF 10.68 million at the end of 2024 to CHF 7.33 million by September 2025. The company’s operating loss for the nine-month period was CHF 2.04 million, with significant reductions in cash and cash equivalents, which stood at CHF 2.19 million, down from CHF 3.34 million at the start of the year.

Despite the financial setbacks, Addex Therapeutics continues to focus on its strategic initiatives, including investments in early-stage R&D companies and maintaining collaborations with partners like Neurosterix Group. The company also raised CHF 1.14 million from the sale of treasury shares during the period.

Looking forward, Addex Therapeutics’ management remains cautious, acknowledging the need for additional capital to sustain operations beyond mid-2026. The company is exploring various funding options, including public or private financings and collaboration agreements, to support its ongoing research and development efforts.